Mehmet Sezai TAŞBAKAN, Oğuz KILINÇ, Canan GÜNDÜZ, Ayşın ŞAKAR COŞKUN, Aykut ÇİLLİ, Abdullah SAYINER

Factors affecting treatment success in community-acquired pneumonia

Background/aim: Treatment failure in hospitalized patients with community-acquired pneumonia is a major cause of mortality. The aim of this study was to evaluate the factors affecting treatment success in community-acquired pneumonia. Materials and methods: A total of 537 patients (mean age: 66.1 ± 15.8 years, 365 males) registered to the Turkish Thoracic Society Pneumonia Database were analyzed. Of these, clinical improvement or cure, defined as treatment success, was achieved in 477, whereas 60 patients had treatment failure and/or died. Results: Lower numbers of neutrophils (5989.9 ± 6237.3 vs. 8495.6 ± 7279.5/mm3 ), higher blood urea levels (66.1 ± 42.1 vs. 51.2 ± 38.2 mg/dL), higher Pneumonia Severity Index (PSI) scores (123.3 ± 42.6 vs. 96.3 ± 32.9), higher CURB-65 scores (2.7 ± 1.2 vs. 2.2 ± 0.9), lower PaO2 /FiO2ratios (216.3 ± 86.8 vs. 269.9 ± 65.6), and the presence of multilobar (33.3% vs. 16.4%) and bilateral (41.7% vs. 18.9%) radiologic infiltrates were related to treatment failure. The PSI score and PaO2 /FiO2ratio were independent parameters affecting treatment results in multivariate linear regression analysis (P < 0.001). Conclusion: The risk of treatment failure is high in patients with severe pneumonia and with respiratory failure. Effective treatment and close monitoring are required for these cases.

PDF

___

1. Menendez R, Torres A. Treatment failure in communityacquired pneumonia. Chest 2007; 132: 1348-1355.
2. Garcia Vidal C, Carratala J. Early and late treatment failure in community acquired pneumonia. Sem Resp Crit Care M 2009; 30: 154-160.
3. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: 27-72.
4. Özlü T, Bülbül Y, Alataş F, Arseven O, Coşkun AŞ, Çilli A, Ekim N, Erdem H, Gürsel G, Hatipoğlu ON et al. Türk Toraks Derneği erişkinlerde toplumda gelişen pnömoni tanı ve tedavi uzlaşı raporu. Türk Toraks Dergisi 2009; 10: 5-9 (in Turkish).
5. Aujesky D, Fine MJ. The Pneumonia Severity Index: A decade after the initial derivation and validation. Clin Infect Dis 2008; 47: 133-139.
6. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, Macfarlane JT, Read RC, Roberts HJ, Levy ML et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 (Suppl. 3): iii1iii55.
7. Arancibia F, Ewig S, Martinez JA. Antimicrobial treatment failures in patients with community acquired pneumonia: causes and prognostic implications. Am J Resp Crit Care 2000; 162: 154-160.
8. Rosón B, Carratalà J, Fernández Sabé N, Tubau F, Manresa F, Gudiol F. Causes and factors associated with early failure in hospitalized patients with community acquired pneumonia. Arch Intern Med 2004; 164: 502-508.
9. Marre JT, Lau CY, Wheeler SL, Wong CJ, Feagan BG. Predictors of symptom resolution in patients with community-acquired pneumonia. Clin Infect Dis 2000; 31: 1362-1367.
10. Sirvent JM, Carmen de la Torre M, Lorencio C, Tache A, Ferri C, Garcia-Gil J, Torres A. Predictive factors of mortality in severe community-acquired pneumonia: a model with data on the first 24 h of ICU admission. Medicina Intensiva 2013; 37: 308-315.
11. Menéndez R, Cavalcanti M, Reyes S. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 2008; 63: 447-452.
12. Coelho L, Póvoa P, Almeida E. Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Crit Care 2007; 11: R92.
13. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in communityacquired pneumonia. Am J Med 2008; 121: 219-225.
14. Bruns AHW, Oosterheert JJ, Hak E, Hoepelman AIM. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J 2008; 32: 726-732.
15. Krüger S, Ewig S, Marre R, Papassotiriou J, Richter K, von Baum H, Suttorp N, Welte T. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008; 31: 349-355.
16. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, Reed C, Grijalva CG, Anderson EJ, Courtney DM et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 2015; 373: 415-427.
17. Brown SM, Dean NC. Defining and predicting severe community-acquired pneumonia. Curr Opin Infect Dis 2010; 23: 158-164.
18. Charles PGP, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, Wright AA, Ramirez JA, Christiansen KJ, Waterer GW et al. SMART-COP: A tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008; 47: 375-384.